Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
19.33
+0.86 (4.66%)
Mar 6, 2026, 4:08 PM HKT
HKG:1877 Revenue
In the year 2025, Shanghai Junshi Biosciences had annual revenue of 2.50B CNY with 28.23% growth. Shanghai Junshi Biosciences had revenue of 692.54M in the quarter ending December 31, 2025, with 2.28% growth.
Revenue
2.50B CNY
Revenue Growth
+28.23%
P/S Ratio
11.56
Revenue / Employee
935.74K CNY
Employees
2,670
Market Cap
32.13B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.50B | 550.10M | 28.23% |
| Dec 31, 2024 | 1.95B | 445.77M | 29.67% |
| Dec 31, 2023 | 1.50B | 49.06M | 3.38% |
| Dec 31, 2022 | 1.45B | -2.57B | -63.89% |
| Dec 31, 2021 | 4.02B | 2.43B | 152.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 3SBio | 9.94B |
| Genscript Biotech | 6.50B |
| Shanghai Henlius Biotech | 6.35B |
| RemeGen | 3.62B |
| Zai Lab | 3.58B |
| Duality Biotherapeutics | 2.38B |
| InnoCare Pharma | 1.56B |
| Biocytogen Pharmaceuticals (Beijing) | 1.53B |
Shanghai Junshi Biosciences News
- 3 months ago - Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis - GlobeNewsWire
- 3 months ago - Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC - GlobeNewsWire
- 5 months ago - Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients - GlobeNewsWire
- 6 months ago - Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints - GlobeNewsWire
- 6 months ago - TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer - GlobeNewsWire
- 6 months ago - Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates - GlobeNewsWire